register

News & Trends - Pharmaceuticals

Arrotex boosts respiratory portfolio to $263m with new Boehringer Ingelheim partnership

Health Industry Hub | February 6, 2020 |

Arrotex Pharmaceuticals is today announcing a strategic partnership with Boehringer Ingelheim for the exclusive Australian reseller rights to respiratory brand Spiriva.

Used for the treatment of chronic obstructive pulmonary disease (COPD), the Spiriva brand currently has a market value of AUD 34 million, increasing Arrotex’ respiratory portfolio to AUD 263.5 million.

Following the 2019 merger of Apotex and Arrow Pharmaceuticals, the combined Arrotex entity now promotes GSK’s Seretide, Pavtide (Seretide authorised generic), Flixotide and Ventolin brands along with AstraZeneca’s respiratory brands Symbicort, Pulmicort, Omnaris, Alvesco, Bricanyl and Oxis.

Arrotex told Health Industry Hub that GSK, AstraZeneca and Boehringer Ingelheim will continue to promote these brands to GPs via their internal field forces. Arrotex’s extensive pharmacy sales team will promote the respiratory products to all community pharmacies.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our proven digital media solutions developed by industry for industry.

Lisa Golden, Arrotex Chief Commercial Officer said: “Strategic partnerships such as this new Boehringer Ingelheim arrangement, as well as existing collaborations with GSK and AstraZeneca, represent a unique element of the Apotex and Arrow offer to pharmacy.

“Through our strategic partnerships, Arrotex creates value for Australian community pharmacy, by offering access to brand product discounts that would otherwise be unavailable to our customers. This is an example of Arrotex’ unique approach to value creation for our customers who are operating in the competitive retail pharmacy market,” she said.

The partnership with Boehringer Ingelheim will take effect 10 February 2020 and Apotex and Arrow will soon contact pharmacies with details of commercial arrangements.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

You may also like Novartis’ new drug – an attractive option in AMD treatment


Human Resources

The return-to-office debate: Where are we in the pendulum's swing?

The return-to-office debate: Where are we in the pendulum’s swing?

Health Industry Hub | May 24, 2024 |

People & Culture: The evolution of hybrid and flexible workplaces has yielded mixed results across the healthcare sector, with some […]

More


News & Trends - MedTech & Diagnostics

Cardinal Health launches local facility for reprocessing of single-use medical devices

Cardinal Health launches local facility for reprocessing of single-use medical devices

Health Industry Hub | May 24, 2024 |

MedTech & Diagnostics News: Cardinal Health is set to launch a cutting-edge facility in Australia dedicated to the reprocessing of […]

More


Medical

New ophthalmic centre to partner on pharma and medtech clinical trials

New ophthalmic centre to partner on pharma and medtech clinical trials

Health Industry Hub | May 24, 2024 |

Medical: The Victorian Deputy Premier and Minister for Medical Research, the Hon Ben Carroll, has launched a cutting-edge ophthalmic clinical […]

More


News & Trends - Pharmaceuticals

Private sector, government and academia gather to tackle barriers in vaccine value chain

Private sector, government and academia gather to tackle barriers in vaccine value chain

Health Industry Hub | May 24, 2024 |

Pharma News: An ‘invite only’ vaccine thought leadership event, aimed at addressing gaps in Australia’s vaccine ecosystem and maximising the […]

More


This content is copyright protected. Please subscribe to gain access.